AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies with RSV Antibody

  AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies with RSV

Business Wire

AMSTERDAM -- July 2, 2014

AIMM Therapeutics, a leading human therapeutic antibody company, today
announced that its partner MedImmune, LLC, the global biologics unit of
AstraZeneca, has initiated phase I clinical studies with MEDI8897, a
best-in-class antibody for the treatment of respiratory syncytial virus (RSV)
infections in young, at risk children. MEDI8897 originated from AIMM’s D25
antibody. Under the terms of their partnering agreement, AIMM will receive a
non-disclosed milestone payment from MedImmune.

D25 was developed from immortalized B cells of an individual exposed to RSV
utilizing AIMM’s proprietary antibody technology platform. Preclinical studies
have shown that D25 neutralizes RSV with high efficiency by recognizing a
unique epitope on the prefusion structure of the F protein expressed on the
virus coat.

“MedImmune is the world leader in RSV infection drug development so the
validation associated with the initiation of clinical studies with MEDI8897 is
very pleasing to see. This milestone is further confirmation of AIMM’s unique
capabilities to discover exceptional human antibodies, with high therapeutic
potency, against biological targets that normally are difficult to address,”
said Dr. Jan de Vries, AIMM’s CEO.

MedImmune’s Head of Research Dr. Yong-Jun Liu added: “We are excited that our
partnership with AIMM Therapeutics resulted in the development of a powerful
RSV antibody aimed at preventing the high morbidity and mortality of RSV
infections in young children at risk.”

About AIMM Therapeutics

AIMM Therapeutics (AIMM) is a leading antibody company that based on its
synergistic, state-of-the-art antibody technology platform develops high
affinity human monoclonal antibodies directly from immortalized and selected B
cells of individuals who produce antibodies with high therapeutic value and of
a variety of non-human species, including rabbits. AIMM antibodies can be
further affinity matured in a proprietary process that does not require
molecular engineering. AIMM has a broad product pipeline targeted at various
cancers and chronic infections. AIMM has two antibodies in clinical trials and
has partnered with companies such as MedImmune/ AstraZeneca, Genentech/Roche,
Johnson & Johnson and Cosmo Pharmaceuticals. For more information:


AIMM Therapeutics
Jan de Vries, CEO
Tel: +31 (0)20 5662145
Halsin Partners
Mike Sinclair
Tel: +44 (0)20 7318 2955
Press spacebar to pause and continue. Press esc to stop.